PT - JOURNAL ARTICLE AU - Steven Riley AU - Kylie E. C. Ainslie AU - Oliver Eales AU - Caroline E. Walters AU - Haowei Wang AU - Christina Atchison AU - Claudio Fronterre AU - Peter J. Diggle AU - Deborah Ashby AU - Christl A. Donnelly AU - Graham Cooke AU - Wendy Barclay AU - Helen Ward AU - Ara Darzi AU - Paul Elliott TI - High and increasing prevalence of SARS-CoV-2 swab positivity in England during end September beginning October 2020: REACT-1 round 5 updated report AID - 10.1101/2020.10.12.20211227 DP - 2020 Jan 01 TA - medRxiv PG - 2020.10.12.20211227 4099 - http://medrxiv.org/content/early/2020/10/14/2020.10.12.20211227.short 4100 - http://medrxiv.org/content/early/2020/10/14/2020.10.12.20211227.full AB - Background REACT-1 is quantifying prevalence of SARS-CoV-2 infection among random samples of the population in England based on PCR testing of self-administered nose and throat swabs. Here we report results from the fifth round of observations for swabs collected from the 18th September to 5th October 2020. This report updates and should be read alongside our round 5 interim report.Methods Representative samples of the population aged 5 years and over in England with sample size ranging from 120,000 to 175,000 people at each round. Prevalence of PCR-confirmed SARS-CoV-2 infection, estimation of reproduction number (R) and time trends between and within rounds using exponential growth or decay models.Results 175,000 volunteers tested across England between 18th September and 5th October. Findings show a national prevalence of 0.60% (95% confidence interval 0.55%, 0.71%) and doubling of the virus every 29 (17, 84) days in England corresponding to an estimated national R of 1.16 (1.05, 1.27). These results correspond to 1 in 170 people currently swab-positive for the virus and approximately 45,000 new infections each day. At regional level, the highest prevalence is in the North West, Yorkshire and The Humber and the North East with strongest regional growth in North West, Yorkshire and The Humber and West Midlands.Conclusion Rapid growth has led to high prevalence of SARS-CoV-2 virus in England, with highest rates in the North of England. Prevalence has increased in all age groups, including those at highest risk. Improved compliance with existing policy and, as necessary, additional interventions are required to control the spread of SARS-CoV-2 in the community and limit the numbers of hospital admissions and deaths from COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was funded by the Department of Health and Social Care in England.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Research ethics approval was obtained from the South Central-Berkshire B Research Ethics Committee (IRAS ID: 283787).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated or analysed, or both, during this study are not publicly available because of governance restrictions.